Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Deep Brain Stimulation Therapy in Movement Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02119611
Recruitment Status : Recruiting
First Posted : April 21, 2014
Last Update Posted : June 7, 2023
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )

Brief Summary:


- In deep brain stimulation (DBS), a device called a neurostimulator is placed in the chest. It is attached to wires in parts of the brain that affect movement. DBS might help people with movement disorders like Parkinson s disease (PD), dystonia, and essential tremor (ET).


- To provide DBS treatment to people with some movement disorders.


- Adults 18 years and older with PD, ET, or certain forms of dystonia.


  • Participants will be screened with medical history and physical exam. They will have blood and urine tests and:
  • MRI brain scan. The participant will lie on a table that slides in and out of a metal cylinder with a magnetic field. They will be in the scanner about 60 minutes. They will get earplugs for the loud noises. During part of the MRI, a needle will guide a thin plastic tube into an arm vein and a dye will be injected.
  • Electrocardiogram. Metal disks or sticky pads will be placed on the chest, arms, and legs. They record heart activity.
  • Chest X-ray.
  • Tests of memory, attention, concentration, thinking, and movement.
  • Eligible participants will have DBS surgery. The surgery and hospital care afterward are NOT part of this protocol.
  • Study doctors will see participants 3 4 weeks after surgery to turn on the neurostimulator.
  • Participants will return every month for 3 months, then every 3 months during the first year, and every 6 months during the second year. Each time, participants will be examined and answer questions. DBS placement will be evaluated with MRI. The neurostimulator will be programmed. At two visits, participants will have tests of movements, thinking, and memory....

Condition or disease Intervention/treatment Phase
Parkinson's Disease Device: Deep Brain Stimulation management Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Deep Brain Stimulation Therapy in Movement Disorders
Actual Study Start Date : April 2, 2014
Estimated Primary Completion Date : December 1, 2030
Estimated Study Completion Date : December 1, 2030

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Device: Deep Brain Stimulation management
The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.

Primary Outcome Measures :
  1. To provide DBS therapy and follow-up management [ Time Frame: two years ]
    a. Severity of PD motor symptoms (measured by the UPDRS III scale) b. Changes in dystonia severity (measured by the Burke-Fahn-Marsden (BFM) dystonia rating scale (Burke et al., 1985) c. Changes in tremor severity (measured by the Tremor Rating Scale (TRS)) d. Levels of effective drug therapy for PD patients using the Levodopa Equivalent Drug Dosing (LEDD) e. Changes in behavior, performance of activities of daily living and complications of therapy as measured by the UPDRS I, II, and IV scales 2. To evaluate effects of DBS before and 1 year after surgery on quality of life: a. For PD patients (measured by UPDRS part II and other scales such as the PDQ-39) b. For the Dystonia and ET patients (measured by the SF-12 scale) 3. To evaluate radiographic correlation of DBS electrode position and clinical changes 4. To evaluate neurophysiological mechanisms of DBS and relevant basal ganglia physiology

  2. To maintain a cohort of patients treated with DBS who can participate in other NIH protocols addressing the efficacy of functional surgery and the relevant physiology [ Time Frame: ongoing ]
    To potentially enroll subjects in other NIH studies.

  3. Data collection [ Time Frame: ongoing ]
    All the data collected will be an outcome of standard of care and all analyses will be retrospective

Secondary Outcome Measures :
  1. To access other clinical outcome measures related to response to therapy [ Time Frame: 2 years ]
    Data collection

  2. To correlate radiographic data related to DBS electrode position with clinical changes [ Time Frame: 2 years ]
    Data collection

  3. To collect physiology data correlated with motor and cognitive function in these [ Time Frame: 2 years ]
    Data collection

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

To be eligible for entry into the study, candidates must meet all the following criteria:

  • Be 18 years of age or older.
  • Able to comply with study procedures and provide informed consent.
  • Have a clinical diagnosis of idiopathic PD, primary dystonia, or ET:

    • The diagnosis of idiopathic PD will be based on the UK Brain Bank Criteria, and confirmed by the Movement Disorders Neurologists in the NIH Parkinson Clinic.
    • The diagnosis of primary (generalized or segmental), hemidystonia, or cervical dystonia will be confirmed on clinical examination in the NIH Movement Disorders Clinic.
    • The diagnosis of ET will be confirmed on clinical examination in the NIH Movement Disorders Clinic (the diagnosis of ET will be based on bilateral, largely symmetric postural or kinetic tremor involving hands and forearms that is visible and persistent. Additional or isolated tremor in head may be present but there should be the absence of abnormal posturing).
  • History of appropriate response to dopaminergic medication, with at least a 30% improvement in motor UPDRS with L-DOPA by history or in-clinic testing, for the PD patients. OR

    --Patients with tremor-dominant PD that do not respond to dopaminergic therapy and that exhibit a tremor score of at least 2 for tremor severity on at least one side of the body on the motor UPDRS examination.

  • Unsatisfactory clinical response to maximal medical management (with trials of both higher and lower doses of drugs), including:
  • For PD patients:

    • good benefit from dopaminergic medication but associated with insufficient duration of action or unacceptable side-effects OR
    • intractable disabling motor fluctuations (severe off periods, dyskinesias, or freezing spells) OR
  • For ET and dystonia:

    --intractable symptoms of ET or dystonia impacting at least 2 activities of daily living.

  • Interested in being evaluated to undergo DBS, if indicated, to treat medically refractory movement disorder or Patients already implanted with DBS for continued management


For those who have not had DBS:

Candidates will be excluded if they meet any of the following criteria:

  • Clinically significant medical disease that would increase the risk of developing pre- or postoperative complications, including but not limited to uncontrolled systemic hypertension with values above 170/100; unstable heart disease; unstable respiratory disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation which cannot be interrupted;
  • Evidence of secondary or atypical parkinsonism/dystonia/tremor as suggested by:

    1. History of stroke, exposure to toxins, neuroleptics, or encephalitis
    2. Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze palsy, or multiple systems atrophy.
    3. MR-imaging with evidence indicative of secondary disease such as tumor, or stroke, which could cause the movement disorder.
  • Dementia as evidenced by formal neuropsychological evaluation, Mattis Dementia Rating Scale (DRS-2) score, and clinical evaluations.
  • Unable to complete cognitive assessments and testing necessary to adequately evaluate risks and benefits of surgery.
  • Clinically signficiant or unstable psychiatric disorder such as severe depression or anxiety, which, in the opinion of the investigators would increase the risk of developing postoperative complications.
  • Unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small closed spaces (have claustrophobia), or cannot lie comfortably on their back for up to one hour.
  • Pregnant women.
  • Otherwise not eligible for DBS surgery, for example known inability to undergo anesthesia

For those who have had DBS:

-Contra-indications for ongoing stimulation, such as intractable side effects of DBS despite stimulation parameter adjustment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02119611

Layout table for location contacts
Contact: Irene H Dustin, C.R.N.P. (301) 402-4479
Contact: Debra J Ehrlich, M.D. (301) 443-7888

Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY dial 711   
Sponsors and Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Layout table for investigator information
Principal Investigator: Debra J Ehrlich, M.D. National Institute of Neurological Disorders and Stroke (NINDS)
Additional Information:
Layout table for additonal information
Responsible Party: National Institute of Neurological Disorders and Stroke (NINDS) Identifier: NCT02119611    
Other Study ID Numbers: 140086
First Posted: April 21, 2014    Key Record Dates
Last Update Posted: June 7, 2023
Last Verified: March 6, 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: .The DBS programing and management provided in this protocol is standard of care and all data is obtained in the course of standard of care treatment and data will be analyzed retrospectively. Since many patients continue to receive ongoing care through this protocol, it is unclear whether it will be feasible to make individual patient data available. This will likely depend on the specific analysis and result.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) ):
Deep Brain Stimulation
Movement Disorders
Parkinson's Disease
Essential Tremor
Tourette Syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Movement Disorders
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases